🫀 ESC Congress 2026 — Day 1 Roundup (Hot Line 1)

Munich, Germany — Friday, August 28, 2026. ESC Congress 2026 opened with Hot Line 1, spanning amyloid cardiomyopathy, nonobstructive HCM, AF anticoagulation thresholds, endocarditis antibiotic duration, and CMR-guided ICD selection. Key data and clinical takeaways from all five presentations are summarized below.

---

🧬 CARDIO-TTRansform: Eplontersen Misses Primary Endpoint in ATTR-CM

The largest-ever ATTR-CM trial randomized 1,432 patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (mean age 72; 57% on a baseline TTR stabilizer) to eplontersen 45 mg SC every 4 weeks or placebo. The composite primary endpoint of CV mortality plus recurrent CV events through week 140 was not met (rate ratio 0.89, 95% CI 0.73–1.09, P = 0.277), despite robust on-target TTR suppression.

A prespecified subgroup of patients not on a baseline stabilizer (monotherapy) showed a nominally significant reduction in events, while those already on a stabilizer derived no incremental benefit — raising questions about background therapy saturation or trial timing relative to disease stage. Safety was consistent with prior eplontersen data.

Presenters framed this as a signal for further exploration in monotherapy or earlier-stage populations rather than a closed door for TTR silencing in ATTR-CM.

Coverage:
CARDIO-TTRansform: Eplontersen Misses Primary Endpoint in ATTR-CM

💊 ACACIA-HCM: Aficamten Positive in Nonobstructive HCM

ACACIA-HCM randomized 517 symptomatic nonobstructive HCM patients (mean LVEF 68%, mean KCCQ-CSS 65.7) to aficamten (titrated 5–20 mg) or placebo. At week 36, aficamten produced a greater KCCQ-CSS improvement (11.4 vs 8.4 points, P = 0.02, widening to 7.0 points by week 72), higher peak VO2 (+0.64 vs −0.03 mL/kg/min, P = 0.003), and more ≥1-class NYHA improvement (41.9% vs 27.8%).

A composite responder analysis (symptoms, exercise capacity, LAVI, septal e′, NT-proBNP) showed a "clinical response" (≥3 domains) in 53% vs 13% (P < 0.001). Reversible LVEF reduction <50% occurred in 10.5% vs 0.8%; 2.7% dropped below 40% and paused dosing, with two permanent discontinuations. LVEF normalized after washout.

With no approved pharmacotherapy currently available for this phenotype, the benefit-risk profile is viewed as sufficient to support regulatory filing, contingent on LVEF monitoring similar to a REMS program.

Full coverage:
Aficamten Wins in Nonobstructive Hypertrophic Cardiomyopathy: ACACIA-HCM

🩸 SINGLE-AF: First RCT Evidence for DOACs at Intermediate CHA2DS2-VASc Risk

Current Class IIa recommendations for anticoagulation at intermediate stroke risk (CHA2DS2-VASc 1 in men, 2 in women) rest on conflicting observational data. SINGLE-AF randomized 1,803 such patients (mean age 60.4; 71.8% paroxysmal AF) to DOAC (apixaban or rivaroxaban) versus no routine anticoagulation.

At 24 months, the composite of stroke, systemic embolism, ISTH major bleeding, or CV death occurred in 0.5% (DOAC) vs 1.5% (control) (HR 0.31, 95% CI 0.10–0.94), driven mainly by fewer strokes (3 vs 10 events). Serious adverse events were similar between arms (8.9% vs 9.3%).

Given the small absolute event count, this is regarded as hypothesis-generating rather than practice-changing; CKD was an exclusion criterion, and generalizability outside the Korean cohort is uncertain. Larger, more heterogeneous confirmatory trials are needed before any guideline revision.

Full coverage:
DOACs Benefit AF Patients With Intermediate Stroke Risk: SINGLE-AF

💉 POET II: Response-Tailored Antibiotic Duration Noninferior in Left-Sided IE

Building on POET I's oral step-down strategy, POET II randomized 508 clinically stabilized patients with streptococcal, S. aureus, or E. faecalis left-sided infective endocarditis to response-tailored discontinuation (median 26 days total therapy) versus standard 4–6 week duration (median 41 days).

The primary safety endpoint (death, unplanned surgery, or symptomatic embolism at 6 months) met noninferiority: 8.2% (tailored) vs 10.7% (standard), P < 0.001. Days alive without antibiotics favored the tailored arm (183 vs 169 days, P < 0.001 for superiority). Relapse was more frequent with tailored therapy (~5% vs 1.6%, P = 0.04), driven largely by E. faecalis (6.4% relapse rate); most relapses were uncomplicated and managed medically.

Discussants endorsed a shift toward personalized, stabilization-criteria-driven duration, with caution advised for enterococcal endocarditis and implementation limited to high-volume endocarditis centers with rigorous stabilization protocols.

Full coverage:
POET II Supports Shorter Antibiotic Course in Infective Endocarditis

🧲 CMR GUIDE: Scar Burden Doesn't Clearly Extend ICD Benefit to LVEF 36–50%

Current primary-prevention ICD criteria are anchored to LVEF ≤35%, leaving patients with mild-to-moderate systolic dysfunction unaddressed despite known arrhythmic risk conferred by myocardial scar. CMR GUIDE randomized 353 patients with ischemic or nonischemic cardiomyopathy, LVEF 36–50%, and LGE-positive scar on CMR to ICD versus implantable loop recorder.

The composite primary endpoint (SCD plus hemodynamically significant VA) was not met (7.8% vs 9.2%; HR 0.76, 95% CI 0.37–1.58). SCD as a standalone endpoint was reduced 72% with ICD (1.7% vs 5.8%; HR 0.26), and a significant age interaction (P = 0.01) showed benefit confined to patients <70 years (HR 0.28) with a signal toward harm in those ≥70 (HR 2.33). NNT over the 6.3-year median follow-up was 24.

Discussants characterized this as absence of evidence rather than evidence of absence, given underpowering from lower-than-expected event rates. No guideline change is anticipated pending a properly powered, age-stratified trial.

Full coverage:
Scarring Doesn't Tip the Scale Towards ICDs in Cardiomyopathy With LVEF of 36–50%

---

📚 References

CARDIO-TTRansform (Maurer MS, et al.):
Rationale and Design of CARDIO-TTRansform. Circ Heart Fail. 2026;doi:10.1161/CIRCHEARTFAILURE.126.014205 (outcomes publication pending; design paper linked)

ACACIA-HCM (Masri A, et al.):
Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy. N Engl J Med. 2026;doi:10.1056/NEJMoa2603021

SINGLE-AF (Kim D, et al.):
Anticoagulation for atrial fibrillation with intermediate stroke risk. N Engl J Med. 2026;doi:10.1056/NEJMoa2607978

POET II (Bundgaard H, et al.):
Response-tailored or standard-duration antibiotic treatment for infective endocarditis. N Engl J Med. 2026;doi:10.1056/NEJMoa2607887

CMR GUIDE (Selvanayagam JB, et al.):
Cardiovascular magnetic resonance to guide defibrillator implantation for LVEF of 36% to 50%. JAMA. 2026.

Source reporting: TCTMD, HCPLive, ESC Congress 2026 (Munich). Summarized and paraphrased from original coverage; consult linked primary publications for full methodology and data.

ESC Congress 2026: A Hot Line Preview from Munich

The European Society of Cardiology Congress returns August 28–31, this year in Munich, and it’s shaping up to be one of the most data-dense meetings in recent memory. More than 30,000 clinicians, researchers, and journalists are expected in the city for four days that include 12 Hot Line sessions covering 59 late-breaking trials, plus three new guidelines and an updated universal definition of MI.

AI as the headline theme

Artificial intelligence runs through much of this year’s programming. ESC leadership has framed it as central to how the next generation of cardiologists will need to train — not just reading images faster, but understanding what’s actually been validated. The guiding philosophy: AI as copilot, clinician as pilot. That shows up structurally in a dedicated AI in Practice track (imaging interpretation, risk stratification, decision support) alongside a Digital Cardiology track covering machine learning and mobile health tools.

The guidelines to watch

Three new ESC guidelines drop during the meeting — heart failure management, cardiac rehabilitation, and combined cardiovascular-CKD management — alongside the Fifth Universal Definition of Myocardial Infarction. Any one of these alone would typically anchor a congress.

Friday, August 28 — Hot Line 1

Cardiomyopathy, endocarditis, anticoagulation, and imaging-guided device therapy open the programme.

• CARDIO-TTRansform — eplontersen in transthyretin amyloid cardiomyopathy. Already known to have missed its primary endpoint; the question is why.
• ACACIA-HCM — aficamten in symptomatic nonobstructive HCM, a population with no approved disease-modifying therapy. Topline results were positive.
• SINGLE-AF — anticoagulation strategy in AF patients at intermediate stroke risk.
• POET-II — tailored-duration antibiotic treatment for infective endocarditis.
• CMR GUIDE — cardiac MRI-guided ICD decisions in mild-to-moderate LV systolic dysfunction.

Saturday, August 29 — Hot Lines 2 through 5

Hot Line 2 — prevention and risk reduction

• STAREE — statins in patients over 70. Addresses whether healthy older adults should be started on a statin for CV and dementia-free survival benefit.
• AMUNDSEN — evolocumab given before PCI in acute MI.
• TRANQUILITY — pacibekitug, an IL-6-targeting monoclonal antibody, in CKD patients with elevated hs-CRP.
• REACT — prevalence of silent atherosclerosis across the adult lifespan.
• ENRICH-AF — edoxaban vs non-anticoagulant therapy in AF patients who survived an intracranial hemorrhage.
• DAN-RSV — bivalent RSV prefusion F vaccine for preventing cardiorespiratory hospitalizations.

Hot Line 3 — post-ACS antithrombotic therapy

• LIBREXIA-ACS — milvexian, an oral factor XIa inhibitor, in over 14,000 patients after ACS. One of the most closely watched antithrombotic programs in cardiology right now.
• PREMIUM — aspirin omission at the time of primary PCI for STEMI.
• SWITCH SWEDEHEART — switching from ticagrelor to prasugrel in ACS.
• A-CLOSE — clopidogrel monotherapy vs extended DAPT beyond 12 months after high-risk PCI.
• EPIDAURUS — one month of escalated antiplatelet therapy plus a DOAC, then clopidogrel, in AF patients after PCI for ACS.

Hot Line 4 — chest pain diagnostics

• PRESC1SE-MI — safety and efficacy of the ESC 0/1-hour troponin algorithm.
• 0/1-hour algorithm vs standard care pathways — individual patient-level meta-analysis.
• AIR-STEMI — angiography-derived fractional flow reserve in STEMI.
• TARGET-CTCA — using troponin levels in acute chest pain to guide CT coronary angiography use.

Hot Line 5 — digital health and remote care

• EMAIL-HF — digital strategy for SGLT2 inhibitor implementation in heart failure.
• ADHERE-ASCVD — adaptive digital outreach to promote statin adherence.
• Remote Exercise SWEDEHEART — cluster-randomized crossover trial of telemedicine for cardiac rehab.
• VIRTUES ICD and VIRTUES PM — digital platforms for remote ICD and pacemaker monitoring.

Sunday, August 30 — Hot Lines 6 through 9

Hot Line 6 — heart failure pharmacotherapy

• H-HeFT / Met-HeFT (“DANHEART”) — hydralazine combined with isosorbide dinitrate or metformin, respectively, vs placebo in HFrEF; each paired with a related meta-analysis.
• LUMINARA — AZD5462, a once-daily oral relaxin agonist, in chronic HF.
• PADN-PH-LHD — pulmonary artery denervation for pulmonary hypertension due to left heart failure.
• TIME-HF — team-based collaborative care model in HF.

Hot Line 7 — structural heart disease

• POPular ACE TAVI — routine vs selective protamine to reduce bleeding after TAVI.
• TAVI PCI — timing strategy for patients needing both TAVI and PCI.
• TRIC-I-HF — transcatheter tricuspid intervention strategies in heart failure with severe TR.
• ACASA-TAVI — antithrombotic therapy after TAVI.
• NOTION-4 — subclinical leaflet thrombosis after TAVI.

Hot Line 8 — AF management

• AFFIRMO — integrated care approach in frail, multimorbid older AF patients.
• PVI-SHAM-AF — pulmonary vein isolation vs a sham control for symptom relief.
• NEXAF — reduced exercise intensity among endurance athletes with nonpermanent AF.
• IDEAL-AF — individually tailored low-voltage ablation of fibrotic areas in persistent AF.

Hot Line 9 — hypertension, lipids, cardiometabolic disease

• SHASTA-3/4 — plozasiran, an siRNA degrading mRNA coding for APOC3, in severe hypertriglyceridemia.
• China Rural Hypertension Control Project (CRHCP) — village doctor-led intensive blood pressure intervention.
• ECLIPSE-CKD — salt substitute in CKD, also conducted in China.
• A meta-analysis of BP-lowering treatment across the spectrum of CV risk rounds out the session.

Monday, August 31 — Hot Lines 10 through 12

Hot Line 10 — arrhythmia and device therapy

• ASPIRED — ambulatory ECG vs standard monitoring in acute unexplained syncope.
• DANISH-CRT — targeted LV lead placement in HF patients with prolonged QRS.
• SyncAV PMT — postmarket study of dynamic AV optimization in CRT.
• Syncope-Stopper — up-front pacing vs standard care in high-risk unexplained syncope.
• His-Alternative II — His-bundle vs biventricular pacing in HF.

Hot Line 11

• EVAOLD — reperfusion strategies in elderly patients.
• ISOLEDS — IVUS vs OCT guidance for PCI of distal left main bifurcation lesions.
• CorCal — coronary artery calcium scoring vs pooled cohort equations in primary prevention.
• CoCAP — DAPT vs aspirin monotherapy on graft patency after CABG in ACS patients.

Hot Line 12

• DISCO — acute coronary angiography in resuscitated OHCA patients without ST-elevation.
• HeartRunner Trial — survival after community first-responder activation in OHCA.
• A related study on coronary angiography’s role after OHCA without ST-elevation.
• PRAGUE-26 — catheter-directed thrombolysis for pulmonary embolism.
• LACCS-2 — left atrial appendage closure among patients undergoing cardiac surgery.

Bottom line

Between LIBREXIA-ACS’s scale, STAREE’s implications for statin use in the elderly, and three fresh guideline documents landing mid-congress, this is a meeting where the practical takeaways will likely outlast the headlines. Worth blocking calendar time for the Hot Line replays if you can’t watch live.

When a Promising Heart Drug Meets an Inconvenient Result

A major cardiovascular trial is forcing doctors to reconsider a 25-year-old theory of heart disease.

Cardiology's inflammation theory of heart disease just failed its biggest test yet. Novo Nordisk's ziltivekimab, a drug designed to block the inflammatory chemical IL-6, was tested in more than 6,300 patients with heart disease or advanced kidney disease. It succeeded at its biological job — inflammation markers dropped sharply — but patients on the drug had no fewer heart attacks, strokes, or cardiovascular deaths than those on placebo.

The theory being tested traces back roughly 25 years, to work suggesting that inflammation isn't just a byproduct of clogged arteries but an actual driver of the disease. That idea gained momentum through the 2000s and shaped a wave of drug development. But this isn't the first disappointment: a similarly large 2018 trial of colchicine, an old gout medication, produced nearly the same pattern — inflammation went down, but outcomes stayed flat.

Reaction among cardiologists has been mixed. Some argue the trial or drug choice was flawed, not the underlying science, pointing to years of supporting evidence from lab and population studies. Others are more openly reconsidering whether inflammation is a cause of heart disease at all, or simply a marker of it — comparable to gray hair signaling age rather than causing it. Two more ziltivekimab trials, testing the drug in heart failure and post-heart-attack patients, are due to report results in 2027, and many in the field are waiting to see whether they support or further undercut the theory.

---

References

ZEUS trial results announcement cardiovascularbusiness.com

Trial design, statistics, and market reaction biopharmadive.com

Cardiologist debate over the inflammation hypothesis tctmd.com

Upcoming HERMES and ARTEMIS trial readouts (2027) pharmacally.com

ZEUS trial registry entry (NCT05021835) clinicaltrials.gov

No DOI is available yet, since full peer-reviewed results have not been published. The trial registry link above is the most stable reference until then.

Bempedoic Acid in PAD

Peripheral artery disease (PAD) is a common but often under recognized form of atherosclerotic cardiovascular disease (ASCVD). Bempedoic acid provides a statin-independent option that lowers both cardiovascular and limb events in statin-intolerant patients with PAD.

A subgroup analysis of the CLEAR Outcomes trial assessed bempedoic acid (Nexletol) in 1,624 statin-intolerant PAD patients (from 13,970 total randomized to bempedoic acid 180 mg daily or placebo).

Baseline LDL cholesterol was 139 mg/dL. At 6 months, LDL fell by 23.6% with bempedoic acid vs 1% with placebo. Over a median 40.6-month follow-up, bempedoic acid reduced first major adverse limb events (MALE) by 36% and total MALE by 45%, with event rates of 5.8% vs 8.3%. Benefits were seen by 6 months and continued throughout follow-up. Combined cardiovascular and limb events were also reduced, showing benefit beyond prevention of myocardial infarction and stroke.

Nearly three-quarters of PAD patients had no prior major limb event, yet still had meaningful event rates. This highlights PAD as a high-risk ASCVD condition even without prior revascularization or critical limb ischemia.

These results align with the overall CLEAR Outcomes trial, where bempedoic acid reduced the primary composite cardiovascular endpoint by 13%. The drug inhibits ATP citrate lyase, lowering LDL cholesterol and generally causing fewer muscle-related side effects than statins. Overall safety was similar to placebo, although hyperuricemia and gout occurred more often.

In summary, these findings support treating PAD as established ASCVD and using intensive LDL lowering to reduce both cardiovascular and limb risk. Statins remain first-line when tolerated, but statin-intolerant patients should receive nonstatin therapies such as bempedoic acid, ezetimibe, or PCSK9-targeted agents, guided by LDL levels, risk, and treatment goals.

Clinical takeaway: In statin-intolerant patients with PAD, clinicians should proactively initiate nonstatin LDL-lowering therapy—particularly bempedoic acid—to reduce not only cardiovascular events but also major limb complications, reinforcing PAD as a high-risk ASCVD condition requiring aggressive lipid management.

Clinical Trials · Preventive Cardiology

ZEUS Trial: Ziltivekimab Fails to Cut MACE, Reigniting the Inflammation Debate

A clean biological signal met a flat clinical curve, and the residual-inflammation hypothesis now faces its most consequential stress test yet.

For physicians and physician-investors · August 2026

Ziltivekimab, an investigational interleukin-6 (IL-6) ligand inhibitor, did not reduce major adverse cardiovascular events (MACE) relative to placebo in the phase 3 ZEUS trial.

Topline results, released by drugmaker Novo Nordisk on July 31, 2026, showed a hazard ratio of 0.99 (95% CI 0.88–1.11) for the composite of cardiovascular death, nonfatal MI, or nonfatal stroke.

The result lands despite clear pharmacodynamic success, as ziltivekimab produced the expected reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP).

For an interventional and preventive cardiology audience already weighing whether to act on residual inflammatory risk, ZEUS forces a hard question: does biomarker modulation without outcome benefit undercut the inflammatory hypothesis of atherosclerosis, or simply indict this particular molecule in this particular population?

Trial Design and Topline Findings

ZEUS was a double-blind, placebo-controlled outcomes trial enrolling more than 6,300 adults with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and hsCRP levels of 2 mg/L or higher.

Participants received once-monthly subcutaneous ziltivekimab 15 mg or placebo on top of standard of care.

The fully human monoclonal antibody binds free IL-6, a proximal driver of the hepatic acute-phase response and a cytokine long implicated in plaque instability.

Despite achieving robust target engagement, the biological effect did not translate into a lower rate of the three-point MACE endpoint.

Overall adverse events, serious adverse events, and all-cause mortality were similar between arms.

Consistent with the known class effect of IL-6 pathway blockade, serious infections occurred more frequently with ziltivekimab than with placebo.

Two additional outcomes trials, HERMES in heart failure with preserved ejection fraction and ARTEMIS in post-MI patients, will proceed as planned, with readouts anticipated in the first half of 2027.

Full ZEUS results, including secondary and safety endpoints, are expected at a scientific meeting later in 2026.

Figure 1. Point estimates for MACE hazard ratios across major anti-inflammatory cardiovascular outcomes trials. Teal markers denote neutral trials; amber markers denote trials meeting their primary endpoint. Approximate values for illustration; consult primary sources for exact confidence intervals.

A Recurring Pattern: Target Engagement Without Outcome Benefit

ZEUS is not the first cardiovascular inflammation trial to separate biomarker response from clinical benefit.

CLEAR SYNERGY (OASIS 9), presented in late 2024, found that routine colchicine 0.5 mg daily did not reduce the composite of CV death, MI, stroke, or ischemia-driven revascularization when started within 72 hours of PCI for acute MI, despite a significantly larger CRP reduction in the colchicine arm.

That result stood in contrast to two earlier positive trials, COLCOT and LoDoCo2, which together underpinned the 2023 FDA approval of low-dose colchicine as the first anti-inflammatory agent indicated for cardiovascular risk reduction.

A parallel story played out with canakinumab, an interleukin-1β inhibitor that reduced MACE in the CANTOS trial among post-MI patients with elevated hsCRP, only for its manufacturer to abandon the cardiovascular indication after regulators requested additional safety and net-benefit data.

Across these programs, the common thread is a drug that reliably lowers hsCRP without a consistent, reproducible reduction in hard cardiovascular endpoints across settings and populations.

The 2025 American College of Cardiology scientific statement on inflammation and cardiovascular disease had characterized the evidence linking inflammation to ASCVD as clinically actionable and endorsed hsCRP testing alongside LDL-C in both primary and secondary prevention.

ZEUS does not overturn the prognostic value of hsCRP, but it does sharpen the distinction between hsCRP as a risk marker and IL-6 inhibition as a proven therapeutic strategy.

Why the Signal Might Be Missing

Several explanations are circulating among trialists and are worth weighing rather than treating the inflammatory hypothesis as disproven outright.

One possibility is population selection, since ASCVD-plus-CKD patients carry a mix of atherosclerotic and non-atherosclerotic risk that IL-6 blockade may not adequately address.

A second is timing, as chronic low-grade inflammation in stable outpatients may respond differently to cytokine blockade than the acute inflammatory surge following plaque rupture, a distinction also raised to explain the divergent CLEAR SYNERGY and LoDoCo2 results.

A third is competing risk from the infection signal, since any cardiovascular benefit from reduced plaque inflammation could be partially offset by increased infection-related morbidity in an immunosuppressed cohort.

A fourth is that free IL-6 and hsCRP reduction, while biologically reassuring, may not be adequate surrogates for the specific inflammatory pathways that drive plaque rupture and thrombosis.

Illustrative Case

A 68-year-old with prior MI, PCI to the LAD three years ago, and stage 3a CKD (eGFR 52) presents for a routine follow-up on high-intensity statin and a PCSK9 inhibitor, with LDL-C at goal but hsCRP persistently elevated at 4.2 mg/L on two occasions.

Before ZEUS, this profile might have prompted discussion of an investigational IL-6-targeted approach or reinforced consideration of low-dose colchicine for residual inflammatory risk.

After ZEUS, the practical takeaway is unchanged for colchicine, which retains its FDA indication and guideline standing for chronic, stable ASCVD outside the acute post-MI window studied in CLEAR SYNERGY, while ziltivekimab remains strictly investigational with no near-term path to clinical use in this population.

Agents Targeting the Inflammatory Pathway

Table 1. Selected anti-inflammatory agents studied for cardiovascular risk reduction

Agent	Target	Key CV Trial	CV Outcome	Regulatory Status (CV)
Colchicine (Lodoco, Colcrys, generic; Agepha Pharma/generics)	Microtubule/NLRP3 inflammasome	LoDoCo2, COLCOT; CLEAR SYNERGY neutral in acute post-MI PCI	Positive in chronic stable ASCVD; neutral in acute post-MI	FDA-approved (2023) for established ASCVD/risk reduction
Canakinumab (Ilaris; Novartis, NYSE: NVS)	IL-1β	CANTOS	Positive for MACE in post-MI patients with elevated hsCRP	No CV indication pursued; approved only for autoinflammatory conditions
Ziltivekimab (investigational; Novo Nordisk, NYSE: NVO)	Free IL-6 ligand	ZEUS	Neutral for MACE despite hsCRP/IL-6 reduction	Investigational; not approved for any indication

Financial and Pipeline Context

Novo Nordisk stated the ZEUS outcome will not alter its previously communicated 2026 adjusted operating profit outlook, though it will trigger a non-cash impairment charge in the third quarter of 2026.

As of early August 2026, analyst consensus on Novo Nordisk (NYSE: NVO) was rated a moderate "Buy," with a roughly $47 twelve-month consensus price target reported by aggregated sell-side coverage.

Given that GLP-1 receptor agonists dominate Novo Nordisk's revenue base, the ZEUS readout is a pipeline setback rather than a material threat to the company's near-term financial trajectory, and HERMES/ARTEMIS remain the more consequential ziltivekimab catalysts to watch into 2027.

Colchicine pricing varies substantially by formulation and pharmacy, with generic 0.6 mg colchicine available for roughly $15 to $30 for a 30-tablet supply through GoodRx coupons, while the branded cardiovascular-indicated formulation, Lodoco, carries substantially higher list pricing without a generic alternative currently available.

Stock prices, analyst ratings, and drug pricing shift frequently and should be independently verified before any clinical-financial correlation is drawn.

Clinical Trial Landscape at a Glance

Table 2. Anti-inflammatory cardiovascular outcomes trials: population and design

Trial	Population	N	Comparator	Primary Result
ZEUS	ASCVD + CKD + hsCRP ≥2 mg/L	>6,300	Ziltivekimab 15 mg monthly vs placebo	Neutral (HR 0.99)
CLEAR SYNERGY (OASIS 9)	Acute MI within 72h of PCI	7,062	Colchicine 0.5 mg daily vs placebo	Neutral (HR 0.99)
LoDoCo2	Chronic coronary disease	5,522	Colchicine 0.5 mg daily vs placebo	Positive
COLCOT	Recent MI (≤30 days)	4,745	Colchicine 0.5 mg daily vs placebo	Positive
CANTOS	Prior MI + hsCRP ≥2 mg/L	10,061	Canakinumab (3 doses) vs placebo	Positive at 150 mg dose

Bottom Line

Ziltivekimab achieved clean target engagement in ZEUS but produced no reduction in MACE among patients with ASCVD, CKD, and elevated hsCRP, joining CLEAR SYNERGY and the canakinumab CV-indication withdrawal as further evidence that lowering inflammatory biomarkers does not guarantee a clinical outcome benefit.

Colchicine's FDA-approved indication for chronic, stable ASCVD is unaffected by ZEUS, and hsCRP retains prognostic value, but the bar for a new anti-inflammatory agent to change practice just moved higher, not lower.

HERMES and ARTEMIS, reading out in 2027, will determine whether IL-6 inhibition has a future in heart failure or post-MI populations even after this ASCVD/CKD miss.

Physician education disclaimer: This article is intended for licensed healthcare professionals for educational purposes and does not constitute clinical practice guidance. Treatment decisions should be individualized and based on current FDA labeling, professional society guidelines, and the clinical judgment of the treating physician.

Financial disclaimer: This content is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Stock prices, analyst ratings, and drug pricing are time-sensitive, approximate, and subject to change; verify current data independently before making any financial decision. The author is not a licensed financial advisor.

References

1. Novo Nordisk. Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation. Press release. July 31, 2026.
2. TCTMD. ZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients. August 3, 2026.
3. TCTMD. Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows. October 29, 2024.
4. American College of Cardiology. New ACC Scientific Statement Details Role of Inflammation in CVD. September 29, 2025.
5. TCTMD. Hopes Fade for a CV Indication for Canakinumab: What's Next for the Inflammatory Hypothesis?
6. ClinicalTrials.gov. HERMES (NCT05636176) and ARTEMIS (NCT06118281) trial registrations.

Further Viewing

• Targeting Inflammation in Cardiovascular Disease: From Canakinumab to Colchicine — Cardiology Rounds lecture.
• Antiinflammatory Therapy and Cardiovascular Events — CANTOS trial overview.
• LoDoCo2 – Low-Dose Colchicine in Coronary Disease — ESC Congress 2020 discussion.

© 2026. All trial data current as of publication date; consult primary sources for full results when published.